Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
Corbus Pharmaceuticals Holdings Inc CRBP
$8.97
▼ -0.88%
($-0.08)
🎢 High Beta
📅 Earnings This Week
Open
$9.06
Prev Close
$9.05
Day Range
$8.62 – $9.16
52W Range
$7.12 – $20.56
Market Cap
$166.19M
Beta
2.63
EPS (TTM)
$-5.81
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2014-10-24 |
| Shares Out. | 18,530,000 |
| Website | corbuspharma.com/ ↗ |
| Phone | 16179630103 |
| Employees | 36 |
| Net Income | -$23.0M |
| Free Cash Flow | -$73.7M |
| Total Assets | $144.5M |
| Total Liabilities | $18.1M |
| Equity | $126.3M |
About Corbus Pharmaceuticals Holdings Inc
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Corbus Pharmaceuticals Holdings Inc is a publicly traded company under the ticker symbol CRBP on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
16 analysts (2026-07-01)